The invention provides the use of an extract of a plant of the genus Elephantorrhiza and at least one compound selected from quercitin-3&prime；-O-glucoside, trans-3-O-galloyl-3,3&prime；,5,5&prime；,7-pentahydroxyflavan, taxifolin-3&prime；-O-glucoside, catechin and epicatechin in the preparation of a medicament for the treatment of benign prostatic hyperplasia (BPH). The mode of action is by a route selected from blocking the conversion of testosterone to dihydrotestosterone by inhibiting the 5&alpha；-reductase enzyme or by reducing oxidative stress or both.
